Evidence map›Paper›PMID 32319819›Full record

ArticleAssay and drug development technologies2020

Development of a QPatch-Automated Electrophysiology Assay for Identifying TMEM16A Small-Molecule Inhibitors.

Kathryn A Henckels, David Fong, Jonathan E Phillips

Open access · hybridAbstract read
In one paragraph

Article in Assay and drug development technologies, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Niclosamide potentiates TMEM16A and induces vasoconstriction.The Journal of general physiology · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kathryn A HenckelsDepartment of Process Development, Amgen, Inc., Thousand Oaks, California, USA.
David FongDepartment of Inflammation Discovery Research, Amgen, Inc., Thousand Oaks, California, USA.
Jonathan E PhillipsDepartment of Inflammation Discovery Research, Amgen, Inc., Thousand Oaks, California, USA.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calcium-activated chloride channel, TMEM16A, is involved in airway hydration and bronchoconstriction and is a promising target for respiratory disease. Drug development efforts around channels require an electrophysiology-based assay for identifying inhibitors or activators. TMEM16A has proven to be a difficult channel to record on automated electrophysiology platforms due to its propensity for rundown. We developed an automated, whole-cell, electrophysiology assay on the QPatch-48 to evaluate small-molecule inhibitors of TMEM16A. In this assay, currents remained stable for a duration of roughly 11 min, allowing for the cumulative addition of five concentrations of compounds and resulted in reproducible IC

Indexed as

AutomationDrug DevelopmentHigh-Throughput Screening AssaysAnoctamin-1BenzbromaroneElectrophysiological PhenomenaFluorescenceHEK293 CellsHumansNeoplasm ProteinsNiflumic AcidSmall Molecule LibrariesSoftwareANO1 protein, humanAnoctamin-1BenzbromaroneNeoplasm ProteinsNiflumic AcidSmall Molecule LibrariesANO1drug developmentelectrophysiologyQPatchsmall moleculeTMEM16A

Identifiers

PMID32319819
PMCPMC7268545
OpenAlexW3016946127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.